2364-67-2
2364-67-2
Chemical Structure
L-Palmitoylcarnitine
- CAS No.: 2364-67-2
- Formula:C23H45NO4
- Molecular Weight:399.61
IUPAC Name: (R)-3-(palmitoyloxy)-4-(trimethylammonio)butanoate
InChIKey: XOMRRQXKHMYMOC-OAQYLSRUSA-N
SMILES: CCCCCCCCCCCCCCCC(O[C@H](CC([O-])=O)C[N+](C)(C)C)=O
Biological Activity: L-Palmitoylcarnitine, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine inhibits KATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
L-Palmitoylcarnitine | 99.88% | L-Palmitoylcarnitine, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine inhibits KATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Palmitoylcarnitine-d9 | 99.0% | L-Palmitoylcarnitine-d9 is deuterium labeled L-Palmitoylcarnitine. L-Palmitoylcarnitine, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine inhibits KATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
D-Palmitoylcarnitine chloride | D-Palmitoylcarnitine (chloride) is an ester product. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Palmitoylcarnitine chloride (Standard) | ≥98% | Palmitoylcarnitine chloride (Standard) is the analytical standard of Palmitoylcarnitine chloride (HY-101017). This product is intended for research and analytical applications. Palmitoylcarnitine chloride is a C16:0 long-chain acylcarnitine and an intermediate product of fatty acid oxidation. The level of Palmitoylcarnitine chloride in human prostate cancer tissues is higher than that in non-cancerous tissues. Palmitoylcarnitine chloride can be used in studies related to lipid metabolism associated with prostate cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-Palmitoylcarnitine chloride (Standard) | ≥98% | L-Palmitoylcarnitine (chloride) (Standard) is the analytical standard of L-Palmitoylcarnitine (chloride). This product is intended for research and analytical applications. L-Palmitoylcarnitine chloride, a long-chain acylcarnitine and a fatty acid metabolite, accumulates in the sarcolemma and deranges the membrane lipid environment during ischaemia. L-Palmitoylcarnitine chloride inhibits KATP channel activity, without affecting the single channel conductance, through interaction with Kir6.2. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Dodecanoylcarnitine | 99.75% | Dodecanoylcarnitine ((-)-Lauroylcarnitine) is a medium long-chain acylcarnitine, an intermediate product in key energy metabolic pathways of fatty acid β-oxidation and amino acids catabolism. The abnormal decrease in the Dodecanoylcarnitine levels indicats that mitochondrial fuel metabolism, including fatty acid oxidation is significantly disturbed. Changes in plasma concentrations of Dodecanoylcarnitine are not only associated with type II diabetes, but also with pre-diabetes status. Dodecanoylcarnitine is present in fatty acid oxidation disorders such as long-chain acyl CoA dehydrogenase deficiency, carnitine palmitoyltransferase I/II deficiency, and is also associated with celiac disease. Dodecanoylcarnitine deomonstrates high sensitivities and specificities in predicting asthma. Combined model of Decanoylcarnitine (HY-113069), Dodecanoylcarnitine, PC (16:0/0:0), and Asp Arg Pro can be used as a potential biomarker for the diagnosis of Yin-deficiency-heat syndrome. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tetradecanoylcarnitine (Standard) | 99.85% | Tetradecanoylcarnitine (Standard) is the analytical standard of Tetradecanoylcarnitine. This product is intended for research and analytical applications. Tetradecanoylcarnitine is a human carnitine involved in β-oxidation of long-chain fatty acids. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Stearoylcarnitine | 99.91% | Stearoylcarnitine, a fatty ester lipid molecule, is an endogenous metabolite. Stearoylcarnitine can be used as PKC inhibitor. Stearoylcarnitine accumulates in β cells, leading to arrest of insulin synthesis and energy deficiency in type 2 diabetes mouse. Stearoylcarnitine inhibits lecithin cholesterol acyltransferase (LCAT) in rat and rabbits plasma. Stearoylcarnitine acts as a metabolomics biomarker for Parkinson’s disease. Stearoylcarnitine is a less potent inhibitor of GlyT2. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
DL-Stearoylcarnitine | DL-Stearoylcarnitine is the racemate of Stearoylcarnitine (HY-113202). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Palmitoylcarnitine | 99.97% | Palmitoylcarnitine is a C16:0 long-chain acylcarnitine and an intermediate product of fatty acid oxidation. The level of Palmitoylcarnitine in human prostate cancer tissues is higher than that in non-cancerous tissues. Palmitoylcarnitine can be used in studies related to lipid metabolism associated with prostate cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Pentadecanoyl-L-carnitine chloride | Pentadecanoyl-L-carnitine chloride is a biochemical reagent. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Heptadecanoyl-L-carnitine chloride | Heptadecanoyl-L-carnitine chloride is a biochemical reagent. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
